CPE

Across TCGA pan-cancer cohorts, CPE mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPE data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CPE mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CPE expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where CPE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.345	0.853	<.001	44	view →
PDAC	DFS	Tertile	III,IV	0.968	0.259	.001	30	view →
LSCC	OS	Tertile	II,III,IV	0.751	0.965	.006	13	view →
CCRCC	DFS	Median	II,III,IV	0.430	0.778	.003	13	view →
GBM	DFS	Quartile	All	0.967	0.601	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPE–LUAD (OS)

Open the LUAD breakdown →